期刊文献+

非肌层侵润性膀胱癌的治疗 被引量:9

Treatment of Non-muscle invasive bladder cancer
原文传递
导出
摘要 膀胱癌是一种全球性疾病。在我国泌尿外科肿瘤中的发病率和死亡率均占首位,非肌层侵润性膀胱癌占初发膀胱肿瘤的70%。对膀胱癌的研究已成为目前学术界的热点话题。目前学界对于非肌层侵润性膀胱癌主要采用以外科手术为主的综合治疗方案。为探讨该类肿瘤的治疗方法,本文就近年来对非肌层侵润性膀胱癌的各种治疗措施进行了比较系统的阐述。我们希望能尽可能的找到高效低风险并且经济的方法,为膀胱癌的诊断和治疗提供新途径。 Bladder tumor is a kind of globle disease.It is the first both morbidity and mortality in our urological.Non-muscle in-vasive bladder cancer is accounted for 70% in primary bladder tumors.Reserching the bladder cancer has become a hot topic.The aca-demic world for non-muscle invasive bladder cancer is mainly based in the comprehensive surgical treatment.To explore the treatment of the bladder carcinoma,in this paper,non-muscle invasive bladder cancer is described which compared various treatment systems in recent years.We hope to find some methods because of effectiveness,low risk of complication,and economical saving possibilitily,which can provide an approach for the diagnosis and treatment of the tumor.
出处 《现代生物医学进展》 CAS 2011年第7期1369-1372,共4页 Progress in Modern Biomedicine
关键词 非肌层浸润性膀胱癌 表浅性膀胱癌 治疗 Non-muscle invasivebladder cancer(NBC) Superficial bladder cancer treatment
  • 相关文献

参考文献27

  • 1Parkin MD, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002 [J]. CA Cancer J Clin, 2005,55:74-108.
  • 2Brown FM, Urine cytology. It is still the gold standard for screening? [J]. Urol Cl/n North Am, 2000,27(1):25-37.
  • 3Cells JE, Gromova I, Moreira JM, et al. Impact ofproteomics on blad- der cancer research [J]. Pharmacogenomics, 2004,5(4):381-394.
  • 4曹志成,余坚文,梁荣能.蛋白质组学——引领后基因组时代[J].中国生物工程杂志,2005,25(1):33-38. 被引量:17
  • 5Riordan E, Goligorsky M S. Emerging studies of the urinary proteome: the end of the beginning? [J]. Curr Opin Nephrol Hypertens, 2005,14 (6):579-585.
  • 6Konety BR. Molecular markers in bladder cancer: A critical appraisal [J]. Urol Oncol, 2006,24(4):326-337.
  • 7Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers[J]. Mol Cell Proteomics, 2006,5(10): 1760-1771.
  • 8Divrik RT, Yildirim U, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with TI tumors of the bladder who received intravesical mitomycin:a prospective, randomized clinical trial[J], J Urol, 2006,175:1641-1644.
  • 9Muraro GB, Grifoni R, Spazzafumo L. Endoscopic therapy of superfial bladder cancer in high-risk patients:holmium laser versus transurethral resection[J]. Surg Technol Int, 2005,14:222-226.
  • 10Brausi M, Collette L, Kurth K. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies[J]. Eur Urol, 2002,41:523-531.

二级参考文献28

  • 1Wasinger V C, Cordwell S J, Cerpa-Poljak A, et al. Progress with gene-product mapping of the mollicutes: Mycoplasma genitalium. Eleetrophoresis, 1995, 16(7): 1090-1094.
  • 2Aebersold R. CoasteUafions in a cellular universe. Nature, 2003,422:115-116.
  • 3Collins F S, Green E D, Guttmacher A E, et al. A vision of the future of geaomics research. Nature, 2003, 422: 835-847.
  • 4Patterson S D. Data analysis-the Achilles heel of proteomies.Nature Bioteehnology, 2003, 21:221-222.
  • 5Aebersold R, Mann M. Mass spectrometry-based proteomics.Nature, 2003, 422:198-207.
  • 6Hutches T,Yip T. New desorption strategies for the mass spectrometric analysis of macroraolecules. Rapid Commun Mass Speetrom, 1993, 7:576-580.
  • 7Chakravarti D N, Chakravarti B, Moutsatsos 1. Infonnatic tools for proteome profiling. Computational Proteomics, 2002, Suppl 32:S4-S15.
  • 8Ouellette J.Bioinfonnaties moves into the mainstream. The Industrial Physicist, 2003, 9(6) : 14-18.
  • 9Yip T T C, Chart J W M, Cho W C S, et al. Protein chip array profrling analysis in SARS patients identified serum amyloid A protein as biomarker potentially useful in monitoring the extent of pneumonia. Clinical Oaemistry, ( in press ) 2005, 51 (1) :45- 55.
  • 10Wu W, Hu W, Kavanagh J J. Proteomies in cancer research.International Journal of Gynecological Cancer, 2002, 12(5): 409.

共引文献16

同被引文献71

  • 1邱志磊,牛海涛,孙光.2005年欧洲泌尿外科会议膀胱癌诊断治疗纲要[J].临床泌尿外科杂志,2006,21(4):318-320. 被引量:39
  • 2姚旭东,叶定伟,朱江,李惠明,唐孝达.吉西他滨对膀胱癌细胞系增殖、细胞周期、凋亡的影响[J].中国癌症杂志,2006,16(12):1019-1022. 被引量:9
  • 3曹明,马辰凯,马俊,等.吉西他滨膀胱灌注治疗复发性浅表性膀胱肿瘤的安全性与有效性[J].中华肿瘤杂志,2011,33(5):385-387.
  • 4BREYER BN, WHITSON JM, CARROLL PR, et al. Sequen- tial intravesical gemcitabine and mitomycin C chemotherapy regi- men in patients with non-muscle invasive bladder cancer[J]. Urol Oncol, 2010, 28(5):510-514.
  • 5DI LORENZO G, FEDERICO P, DE PLACIDO Set al. In- creased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review [J]. Crit RevOncol Hematol, 2015, 96(3):534-541.
  • 6HALL MC, CHANG SS, DALBAGNI G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis) :2007 update[J]. J Urol, 2007, 178(6) :2314- 2330.
  • 7KIM WJ. Is 5-AMP-activated protein kinase both jekyll and hyde in bladder cancer? [J]. Int NeurourolJ, 2015, 19(2):55- 66.
  • 8KANDEEL W, ABDELAL A, ELMOHAMADY BN, et al. A comparative study between full-dose and half-dose intravesical immune bacille Calmette-Guerin injection in the management of superficial bladder cancer[J]. Arab J Urol, 2015, 13(4) : 233- 237.
  • 9LIGHTFOOT AJ, BREYER BN, ROSEVEAR HM, et al. Multi-institutional analysis of sequential intravesieal gemeitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer[J]. Urol Oncol, 2014, 32(1) :15-35.
  • 10ROBERTS JT, VON DER MAASE H, et al. Long-term surviv- al results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicia/cisplatin in patients with locally advanced and metastatic bladder cancer[J]. Annals Oncol, 2006, 17(Supplement 5) :v118-v122.

引证文献9

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部